Ni Bai, Wasithep Limvorapitak, Robert Henderson, Yasser Abou Mourad, Shanee Chung, Donna Forrest, Kevin Hay, Florian Kuchenbauer, Stephen Nantel, Sujaatha Narayanan, Thomas Nevill, Maryse Power, Judith Rodrigo, Claudie Roy, David Sanford, Kevin Song, Ryan Stubbins, Heather Sutherland, Cynthia Toze, Jennifer White
{"title":"在髓鞘脱落非血缘关系供体移植手术中，在标准预防 GVHD 的基础上常规添加抗胸腺细胞球蛋白的实际影响：虽然总体存活率没有差异，但在预防移植物抗宿主疾病方面取得了重要成果。","authors":"Ni Bai, Wasithep Limvorapitak, Robert Henderson, Yasser Abou Mourad, Shanee Chung, Donna Forrest, Kevin Hay, Florian Kuchenbauer, Stephen Nantel, Sujaatha Narayanan, Thomas Nevill, Maryse Power, Judith Rodrigo, Claudie Roy, David Sanford, Kevin Song, Ryan Stubbins, Heather Sutherland, Cynthia Toze, Jennifer White","doi":"10.1159/000541071","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Antithymocyte globulin (ATG) has been demonstrated to reduce the incidence of graft-versus-host disease (GVHD); however, it remains controversial whether these gains are offset by an increase in relapse.</p><p><strong>Methods: </strong>We conducted a retrospective historical control study consisting of patients (n = 210) who underwent myeloablative allogeneic hematopoietic stem-cell transplantation (HSCT) from 2014 to 2020.</p><p><strong>Results: </strong>The incidence of acute GVHD was lower in the ATG group (51.4%) than the non-ATG group (control) (70.0%, p = 0.010). The incidence of chronic GVHD was also lower in the ATG group at 1-year (36.4% vs. 62.9%, p < 0.001) and 2-year (40.0% vs. 65.7%, p < 0.001) post-HSCT. The mortality due to GVHD was higher in the control (18.5%) than the ATG group (4.3%; p = 0.024). The severe GVHD-relapse-free survival was higher in the ATG group (36.4%) than the control (12.9%; p < 0.001). Nevertheless, the 2-year overall survival was similar.</p><p><strong>Conclusion: </strong>Our results confirm the effectiveness of ATG in prevention of GVHD in the real-world setting and enhanced GVHD-free survival. An important result is the equalization of overall survival between the ATG and control groups at 1- and 2-year post-HSCT and implies that earlier GVHD-associated mortality may be offset by later relapse mortality producing similar overall survival over time.</p>","PeriodicalId":1,"journal":{"name":"Accounts of Chemical Research","volume":null,"pages":null},"PeriodicalIF":16.4000,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Real-World Impact of Routine Addition of Antithymocyte Globulin to Standard GVHD Prophylaxis in Myeloablative Unrelated Donor Transplants: Important Gains in Graft-versus-Host Disease Prevention though No Difference in Overall Survival.\",\"authors\":\"Ni Bai, Wasithep Limvorapitak, Robert Henderson, Yasser Abou Mourad, Shanee Chung, Donna Forrest, Kevin Hay, Florian Kuchenbauer, Stephen Nantel, Sujaatha Narayanan, Thomas Nevill, Maryse Power, Judith Rodrigo, Claudie Roy, David Sanford, Kevin Song, Ryan Stubbins, Heather Sutherland, Cynthia Toze, Jennifer White\",\"doi\":\"10.1159/000541071\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Antithymocyte globulin (ATG) has been demonstrated to reduce the incidence of graft-versus-host disease (GVHD); however, it remains controversial whether these gains are offset by an increase in relapse.</p><p><strong>Methods: </strong>We conducted a retrospective historical control study consisting of patients (n = 210) who underwent myeloablative allogeneic hematopoietic stem-cell transplantation (HSCT) from 2014 to 2020.</p><p><strong>Results: </strong>The incidence of acute GVHD was lower in the ATG group (51.4%) than the non-ATG group (control) (70.0%, p = 0.010). The incidence of chronic GVHD was also lower in the ATG group at 1-year (36.4% vs. 62.9%, p < 0.001) and 2-year (40.0% vs. 65.7%, p < 0.001) post-HSCT. The mortality due to GVHD was higher in the control (18.5%) than the ATG group (4.3%; p = 0.024). The severe GVHD-relapse-free survival was higher in the ATG group (36.4%) than the control (12.9%; p < 0.001). Nevertheless, the 2-year overall survival was similar.</p><p><strong>Conclusion: </strong>Our results confirm the effectiveness of ATG in prevention of GVHD in the real-world setting and enhanced GVHD-free survival. An important result is the equalization of overall survival between the ATG and control groups at 1- and 2-year post-HSCT and implies that earlier GVHD-associated mortality may be offset by later relapse mortality producing similar overall survival over time.</p>\",\"PeriodicalId\":1,\"journal\":{\"name\":\"Accounts of Chemical Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":16.4000,\"publicationDate\":\"2024-08-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Accounts of Chemical Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1159/000541071\",\"RegionNum\":1,\"RegionCategory\":\"化学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MULTIDISCIPLINARY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Accounts of Chemical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000541071","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0
摘要
导言：抗胸腺细胞球蛋白（ATG）已被证明可降低移植物抗宿主疾病（GVHD）的发病率；然而，这些益处是否会被复发率的增加所抵消仍存在争议：我们进行了一项回顾性历史对照研究，研究对象包括2014年至2020年接受髓溶性异基因造血干细胞移植（HSCT）的患者（n=210）：ATG组急性GVHD发生率（51.4%）低于非ATG组（对照组）（70.0%，P=0.010）。HSCT后1年（36.4% vs. 62.9%，p <0.001）和2年（40.0% vs. 65.7%，p <0.001），ATG组的慢性GVHD发生率也较低。对照组因GVHD导致的死亡率（18.5%）高于ATG组（4.3%；P= 0.024）。ATG 组的严重 GVHD 无复发生存率（36.4%）高于对照组（12.9%；p <0.001）。结论：我们的研究结果证实了ATG治疗的有效性：我们的研究结果证实，ATG在现实世界中有效预防了GVHD，并提高了无GVHD生存率。一个重要的结果是，ATG组和对照组在HSCT后1年和2年的总生存率相同，这意味着早期的GVHD相关死亡率可能会被后期的复发死亡率所抵消，从而在一段时间内产生相似的总生存率。
Real-World Impact of Routine Addition of Antithymocyte Globulin to Standard GVHD Prophylaxis in Myeloablative Unrelated Donor Transplants: Important Gains in Graft-versus-Host Disease Prevention though No Difference in Overall Survival.
Introduction: Antithymocyte globulin (ATG) has been demonstrated to reduce the incidence of graft-versus-host disease (GVHD); however, it remains controversial whether these gains are offset by an increase in relapse.
Methods: We conducted a retrospective historical control study consisting of patients (n = 210) who underwent myeloablative allogeneic hematopoietic stem-cell transplantation (HSCT) from 2014 to 2020.
Results: The incidence of acute GVHD was lower in the ATG group (51.4%) than the non-ATG group (control) (70.0%, p = 0.010). The incidence of chronic GVHD was also lower in the ATG group at 1-year (36.4% vs. 62.9%, p < 0.001) and 2-year (40.0% vs. 65.7%, p < 0.001) post-HSCT. The mortality due to GVHD was higher in the control (18.5%) than the ATG group (4.3%; p = 0.024). The severe GVHD-relapse-free survival was higher in the ATG group (36.4%) than the control (12.9%; p < 0.001). Nevertheless, the 2-year overall survival was similar.
Conclusion: Our results confirm the effectiveness of ATG in prevention of GVHD in the real-world setting and enhanced GVHD-free survival. An important result is the equalization of overall survival between the ATG and control groups at 1- and 2-year post-HSCT and implies that earlier GVHD-associated mortality may be offset by later relapse mortality producing similar overall survival over time.
期刊介绍：
Accounts of Chemical Research presents short, concise and critical articles offering easy-to-read overviews of basic research and applications in all areas of chemistry and biochemistry. These short reviews focus on research from the author’s own laboratory and are designed to teach the reader about a research project. In addition, Accounts of Chemical Research publishes commentaries that give an informed opinion on a current research problem. Special Issues online are devoted to a single topic of unusual activity and significance.
Accounts of Chemical Research replaces the traditional article abstract with an article "Conspectus." These entries synopsize the research affording the reader a closer look at the content and significance of an article. Through this provision of a more detailed description of the article contents, the Conspectus enhances the article's discoverability by search engines and the exposure for the research.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
